-

Medable to Present at Morgan Stanley Global Healthcare Conference

PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., a leading AI technology platform provider for clinical research, today announced that Medable CEO and Co-Founder Michelle Longmire will be presenting a corporate update at the Morgan Stanley Global Healthcare Conference in New York City. The presentation will take place on Tuesday, September 9th 7:45 AM Eastern Time.

About Medable

Medable, a Software as a Service (SaaS) cloud platform, is revolutionizing clinical drug development. Our AI-driven platform, including Agent Studio, enhances speed, scale, and patient access in clinical research. Awarded Best Digital Health Solution by the Galien Foundation, Medable’s platform has been deployed in nearly 400 trials in 70 countries and 120 languages, serving more than one million patients globally. Medable is a privately held, venture-backed company headquartered in Palo Alto, California, and was listed for the second year in a row on the Inc. 5000 in 2024.

Contacts

Media Contact:
Lisa Barbadora, Barbadora INK for Medable
+1 (610) 420-3413
lbarbadora@barbadoraink.com / media@medable.com

Burak Over, SVP, Corporate Development & Investor Relations, Medable
Burak@medable.com

Medable Inc.

Details
Headquarters: Palo Alto, California
CEO: Michelle Longmire
Employees: 350
Organization: PRI

Release Versions

Contacts

Media Contact:
Lisa Barbadora, Barbadora INK for Medable
+1 (610) 420-3413
lbarbadora@barbadoraink.com / media@medable.com

Burak Over, SVP, Corporate Development & Investor Relations, Medable
Burak@medable.com

Social Media Profiles
More News From Medable Inc.

Medable Named a Leader Amid Growing eCOA Adoption

PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., a leading provider of clinical trial technology, today announced it has been named a Leader in Everest Group’s 2025 "Life Sciences Electronic Clinical Outcome Assessment (eCOA) Products PEAK Matrix® Assessment." Medable was recognized among 19 vendors for its strong performance across three key areas: buyer priorities, innovation, and future focus. Medable was named a Leader for its continued investment in AI and machine learning to enhance plat...

Medable Launches The Industry’s First Agentic AI Platform and CRA Agent; Removes Bottlenecks in Clinical Development

PALO ALTO, Calif.--(BUSINESS WIRE)--Medable, the leading technology provider for clinical development, today launched Agent Studio: the industry’s first agentic AI platform purpose-built for life sciences. Agent Studio is a no-code agent-builder that enables clinical teams to quickly custom-configure AI agents. Medable also introduced CRA Agent, an out-of-the-box agent running on Agent Studio that is specifically designed for clinical trial monitoring. Both Agent Studio and CRA Agent will drive...

Medable Launches Partner Program for Faster Clinical Trial Startup, Greater Control, and Transparent Pricing

PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., a leading provider of clinical development technology, today unveiled its new Partner Program, designed to empower contract research organizations (CROs) and other partners with generative AI-driven, self-service eCOA build capabilities for digitally enabled clinical trials. Leveraging the Medable platform, the program eliminates traditional bottlenecks for CROs to accelerate timelines by 50% or more, while delivering administrative and financia...
Back to Newsroom